NanoHybrids develops nanoparticle contrast agents for Photoacoustics, Optical Imaging, Microscopy, Molecular Diagnostic and Theranostic applications.
As nanotechnology rapidly expands into the realms of medicine, there is an unmet need for “smart” nanoparticles capable of homing in on diseased tissue while leaving healthy cells intact. When targeted to specific biomarkers, these nanoparticles can provide critical information about the biology of the disease in the context of the anatomy both in vitro and in vivo.
Our nano-sized contrast agents can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. Our products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches.
NanoHybrids has a layered strategy of product development targeting three broadly related market segments: the preclinical market, in vitro diagnostic assays and clinical applications. Our current line of specially designed gold nanoparticles for the research market presents several advantages over other commercially available nanoparticles including superior thermodynamic properties and higher signal strength.
Our company leverages patented nanotechnology developed within the academic research of its founders at The University of Texas at Austin and M.D. Anderson Cancer Center.